Dawn Maze

905 total citations
62 papers, 370 citations indexed

About

Dawn Maze is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Dawn Maze has authored 62 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 28 papers in Genetics and 18 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Dawn Maze's work include Acute Myeloid Leukemia Research (36 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (23 papers) and Chronic Myeloid Leukemia Treatments (19 papers). Dawn Maze is often cited by papers focused on Acute Myeloid Leukemia Research (36 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (23 papers) and Chronic Myeloid Leukemia Treatments (19 papers). Dawn Maze collaborates with scholars based in Canada, United States and Australia. Dawn Maze's co-authors include Vikas Gupta, Hassan Sibai, Karen Yee, Aaron D. Schimmer, Nadine Shehata, Ann Kinga Malinowski, Prakesh S. Shah, Rouhi Fazelzad, Caroline McNamara and Steven M. Chan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Dawn Maze

55 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dawn Maze Canada	10	220	128	99	93	48	62	370
David R. Czuchlewski United States	11	145 0.7×	142 1.1×	55 0.6×	88 0.9×	49 1.0×	26	402
Gholamreza Toogeh Iran	10	226 1.0×	92 0.7×	63 0.6×	19 0.2×	20 0.4×	37	353
Thamer Sliwa Austria	8	213 1.0×	144 1.1×	114 1.2×	33 0.4×	48 1.0×	29	329
Ihab El‐Hemaidi Saudi Arabia	8	190 0.9×	151 1.2×	60 0.6×	106 1.1×	28 0.6×	20	331
Xiaosha Zhang United States	10	359 1.6×	288 2.3×	138 1.4×	17 0.2×	33 0.7×	22	481
Jaime Garcı́a-Chávez Mexico	9	219 1.0×	78 0.6×	47 0.5×	27 0.3×	20 0.4×	32	311
Serguei A. Castañeda United States	10	137 0.6×	157 1.2×	130 1.3×	26 0.3×	16 0.3×	22	400
Giambattista Bertani Italy	8	302 1.4×	103 0.8×	188 1.9×	29 0.3×	14 0.3×	20	460
Patrizia Guglielmo Italy	10	218 1.0×	172 1.3×	154 1.6×	62 0.7×	14 0.3×	32	411
José Miguel Couselo Spain	9	118 0.5×	59 0.5×	47 0.5×	71 0.8×	27 0.6×	13	332

Countries citing papers authored by Dawn Maze

Since Specialization

Citations

This map shows the geographic impact of Dawn Maze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawn Maze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawn Maze more than expected).

Fields of papers citing papers by Dawn Maze

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawn Maze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawn Maze. The network helps show where Dawn Maze may publish in the future.

Co-authorship network of co-authors of Dawn Maze

This figure shows the co-authorship network connecting the top 25 collaborators of Dawn Maze. A scholar is included among the top collaborators of Dawn Maze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawn Maze. Dawn Maze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Atenafu, Eshetu G., Steven M. Chan, Karen Yee, et al.. (2025). Identifying Risk Factors and Outcome for CNS Involvement in AML. Clinical Lymphoma Myeloma & Leukemia. 25(10). e834–e843.

Richard‐Carpentier, Guillaume, Séverine Cathelin, Lisa Wang, et al.. (2025). Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial. The Lancet Haematology. 12(11). e887–e897.

Maze, Dawn, et al.. (2024). Shared-Care in Complex Malignant Hematology: An Integrative Review Using the RE-AIM Evaluation Framework. Current Oncology. 31(9). 5484–5497. 1 indexed citations

Davidson, Marta, James A. Kennedy, José‐Mario Capo‐Chichi, et al.. (2024). Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN. Blood Advances. 8(5). 1281–1294. 5 indexed citations

Davidson, Marta, Steven M. Chan, Hassan Sibai, et al.. (2024). FLAG-IDA Plus Venetoclax in High-Risk Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia: The Princess Margaret Cancer Center Experience. Blood. 144(Supplement 1). 4273–4273.

Chen, Ruiqi, Eshetu G. Atenafu, Steven M. Chan, et al.. (2024). Outcome of adolescents and young adult acute myeloid leukemia patients compared with middle-aged patients: A single centre retrospective experience. Leukemia Research. 147. 107586–107586.

Atenafu, Eshetu G., Steven M. Chan, Vikas Gupta, et al.. (2023). Impact of Geographical Distance from Quaternary Treatment Center on Clinical Trial Participation, Intensive Induction Chemotherapy, and Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia. Acta Haematologica. 146(5). 366–372. 1 indexed citations

Murphy, Tracy, Jacqueline M. Mason, Brian Leber, et al.. (2023). Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia. 38(3). 502–512. 11 indexed citations

Tierens, Anne, Satoru Shinriki, Adam C. Smith, et al.. (2023). Biallelic disruption of DDX41 activity is associated with distinct genomic and immunophenotypic hallmarks in acute leukemia. Frontiers in Oncology. 13. 1153082–1153082. 3 indexed citations

10.

Chen, Ruiqi, Eshetu G. Atenafu, Xing Liu, et al.. (2023). Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology. 201(4). 645–652. 2 indexed citations

11.

Atenafu, Eshetu G., Taylor Young, Steven M. Chan, et al.. (2022). Safety of re‐challenging adults with acute lymphoblastic leukemia with PEG‐asparaginase‐induced severe hypertriglyceridemia when treated with a pediatric‐inspired regimen. SHILAP Revista de lepidopterología. 4(1). 232–235. 2 indexed citations

12.

LeBlanc, Thomas W., Nigel H. Russell, Charlotte Panter, et al.. (2022). Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making. Oncology and Therapy. 10(2). 421–440. 5 indexed citations

13.

Maze, Dawn. (2022). Myeloproliferative neoplasms in 2022. 1 indexed citations

14.

Davidson, Marta, et al.. (2021). Safety and Efficacy of JAK Inhibitor Therapy in BCR-ABL Negative MPN Patients with Underlying Portal Hypertension. Blood. 138(Supplement 1). 3652–3652.

15.

Puckrin, Robert, Eshetu G. Atenafu, Jaime O. Claudio, et al.. (2020). Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica. 106(1). 56–63. 28 indexed citations

16.

Chen, Ruiqi, Arjun Law, Dawn Maze, et al.. (2020). Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen. Current Oncology. 28(1). 128–137.

17.

Visram, Alissa, Christopher Bredeson, David Allan, et al.. (2018). Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. Blood Cancer Journal. 8(1). 14–14. 6 indexed citations

18.

Bartoszko, Justyna, Tony Panzarella, Caroline McNamara, et al.. (2017). Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study. Clinical Lymphoma Myeloma & Leukemia. 17(11). 774–781. 5 indexed citations

19.

Tay, Jason, David Allan, Sara Beattie, et al.. (2016). Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study. BMJ Open. 6(10). e013483–e013483. 6 indexed citations

20.

Bryant, Adam, Dawn Sheppard, Mitchell Sabloff, et al.. (2014). A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia. Leukemia & lymphoma. 56(1). 135–140. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact